Skeletal Muscle Mass Influences Tolerability and Prognosis in Hepatocellular Carcinoma Patients Treated with LenvatinibHaruki Uojima, Wasaburo Koizumi, Makoto Chuma et al.|Liver Cancer|2019Cited by 91
Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trialMasaaki Kondo, Katsuaki Tanaka, Manabu Morimoto et al.|BMC Cancer|2019Cited by 77
Higher discontinuation and lower survival rates are likely in elderly Japanese patients with advanced hepatocellular carcinoma receiving sorafenibManabu Morimoto, Katsuaki Tanaka, Kazushi Numata et al.|Hepatology Research|2011Cited by 77
Genome-wide association meta-analysis identifies GP2 gene risk variants for pancreatic cancerYingsong Lin, Haruo Mikami, Masato Akiyama et al.|Nature Communications|2020Cited by 62
<p>Safety and Efficacy of Lenvatinib Treatment in Child–Pugh A and B Patients with Unresectable Hepatocellular Carcinoma in Clinical Practice: A Multicenter Analysis</p>Katsuaki Ogushi, Shin Maeda, Makoto Chuma et al.|Clinical and Experimental Gastroenterology|2020Cited by 55